Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy

Investigational New Drugs

Volumn 25, Issue 3, 2007, Pages 277-278

  Stein, C A ^a,b   Goel, Sanjay ^a   Ghavamian, Reza ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Hepatitis; Ketoconazole; Lovastatin; Prostatic neoplasms; Rhabdomyolysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; BICALUTAMIDE; CREATINE KINASE; DOCETAXEL; HYDROCORTISONE; KETOCONAZOLE; LEUPRORELIN; MEVINOLIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS; HUMAN; MALE; METASTASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; RHABDOMYOLYSIS; UNSPECIFIED SIDE EFFECT; URINALYSIS;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HEPATITIS, TOXIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KETOCONAZOLE; LOVASTATIN; MALE; PROSTATIC NEOPLASMS; RHABDOMYOLYSIS; TREATMENT OUTCOME;

EID: 34248670392     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9032-5     Document Type: Article

References (14)

1. Itakura H, Vaughn D, Haller D, O'Dwyer P (2003) Rhabdoymolysis from cytochrome P-450 interaction of ketoconazole and simvastatin in prostate cancer. J Urol 169:613
2. Williams D, Feely J (2002) Pharmacokinetic-pharmacosdynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41:343
3. Gilad R, Laml Y (1999) Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 22:295
4. Neuvonen P, Kantola T, Kivisto K (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332
5. Bays H, Dujovne C (1998) Drug interactions of lipid-altering drugs. Drug Saf 5:355
6. Chung E, Nafziger A, Kazierad D, Bertino J Jr (2006) Comparison of midazolam and simvastatin as cytochrome P450 3A inhibitors. Clin Pharm Ther 79:350
7. East C, Alivizatios P, Grundy S et al (1988) Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 318:47
8. Gullestad L, Nordal K, Berg K et al (1999) Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Transplant Proc 31:2163
9. Tobert J (1988) Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 318:48
10. Tolman K (2000) Defining patient risks from expanded preventive therapies. Amer J Cardiol 85:15E
11. Grimbert S, Pessayre D, Degott C, Benhamou JP (1994) Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci 39:2032-2033
12. Mantell G, Burke MT, Staggers J (1990) Extended clinical safety profile of lovastatin. Am J Cardiol 66:11B-15B
13. http://www.fda.gov/bbs/topics/NEWS/NEW00721.html Downloaded Oct 30, 2006
14. Velayudham L, Farrell G (2003) Drug-induced cholestasis. Expert Opin Drug Saf 2:287